Frontiers in Endocrinology (Nov 2022)
Low-dose aspirin protects unexplained recurrent spontaneous abortion via downregulation of HMGB1 inflammation activation
- Xiaofeng Xu,
- Xiaofeng Xu,
- Xiaofeng Xu,
- Jing Wang,
- Damin Zhu,
- Damin Zhu,
- Damin Zhu,
- Jiaqian Yin,
- Jiaqian Yin,
- Jiaqian Yin,
- Jinxian Liu,
- Jinxian Liu,
- Jinxian Liu,
- Xiao Wu,
- Xiao Wu,
- Xiao Wu,
- Wenjuan Yang,
- Wenjuan Yang,
- Wenjuan Yang,
- Qian Hu,
- Qian Hu,
- Qian Hu,
- Yu Ren,
- Yu Ren,
- Yu Ren,
- Zhiguo Zhang,
- Zhiguo Zhang,
- Zhiguo Zhang,
- Ping Zhou,
- Ping Zhou,
- Ping Zhou,
- Zhaolian Wei,
- Zhaolian Wei,
- Zhaolian Wei,
- Huijuan Zou,
- Huijuan Zou,
- Huijuan Zou,
- Yunxia Cao,
- Yunxia Cao,
- Yunxia Cao
Affiliations
- Xiaofeng Xu
- Reproductive Medicine Center, Department of Obstetrics and Gynecology, the First Affiliated Hospital of Anhui Medical University, Hefei, China
- Xiaofeng Xu
- National Health Commission (NHC) Key Laboratory of Study on Abnormal Gametes and Reproductive Tract (Anhui Medical University), Hefei, China
- Xiaofeng Xu
- Key Laboratory of Population Health Across Life Cycle (Anhui Medical University), Ministry of Education of the People’s Republic of China, Hefei, Anhui, China
- Jing Wang
- Center for Reproductive Medicine, Ma’anshan Maternal and Child Health Hospital, Ma’anshan, Anhui, China
- Damin Zhu
- Reproductive Medicine Center, Department of Obstetrics and Gynecology, the First Affiliated Hospital of Anhui Medical University, Hefei, China
- Damin Zhu
- Anhui Province Key Laboratory of Reproductive Health and Genetics (Anhui Medical University), Hefei, Anhui, China
- Damin Zhu
- Biopreservation and Artificial Organs, Anhui Provincial Engineering Research Center, Anhui Medical University, Hefei, Anhui, China
- Jiaqian Yin
- Reproductive Medicine Center, Department of Obstetrics and Gynecology, the First Affiliated Hospital of Anhui Medical University, Hefei, China
- Jiaqian Yin
- Anhui Province Key Laboratory of Reproductive Health and Genetics (Anhui Medical University), Hefei, Anhui, China
- Jiaqian Yin
- Biopreservation and Artificial Organs, Anhui Provincial Engineering Research Center, Anhui Medical University, Hefei, Anhui, China
- Jinxian Liu
- Reproductive Medicine Center, Department of Obstetrics and Gynecology, the First Affiliated Hospital of Anhui Medical University, Hefei, China
- Jinxian Liu
- Anhui Province Key Laboratory of Reproductive Health and Genetics (Anhui Medical University), Hefei, Anhui, China
- Jinxian Liu
- Biopreservation and Artificial Organs, Anhui Provincial Engineering Research Center, Anhui Medical University, Hefei, Anhui, China
- Xiao Wu
- Reproductive Medicine Center, Department of Obstetrics and Gynecology, the First Affiliated Hospital of Anhui Medical University, Hefei, China
- Xiao Wu
- Anhui Province Key Laboratory of Reproductive Health and Genetics (Anhui Medical University), Hefei, Anhui, China
- Xiao Wu
- Biopreservation and Artificial Organs, Anhui Provincial Engineering Research Center, Anhui Medical University, Hefei, Anhui, China
- Wenjuan Yang
- Reproductive Medicine Center, Department of Obstetrics and Gynecology, the First Affiliated Hospital of Anhui Medical University, Hefei, China
- Wenjuan Yang
- Anhui Province Key Laboratory of Reproductive Health and Genetics (Anhui Medical University), Hefei, Anhui, China
- Wenjuan Yang
- Biopreservation and Artificial Organs, Anhui Provincial Engineering Research Center, Anhui Medical University, Hefei, Anhui, China
- Qian Hu
- Reproductive Medicine Center, Department of Obstetrics and Gynecology, the First Affiliated Hospital of Anhui Medical University, Hefei, China
- Qian Hu
- Anhui Province Key Laboratory of Reproductive Health and Genetics (Anhui Medical University), Hefei, Anhui, China
- Qian Hu
- Biopreservation and Artificial Organs, Anhui Provincial Engineering Research Center, Anhui Medical University, Hefei, Anhui, China
- Yu Ren
- Reproductive Medicine Center, Department of Obstetrics and Gynecology, the First Affiliated Hospital of Anhui Medical University, Hefei, China
- Yu Ren
- Anhui Province Key Laboratory of Reproductive Health and Genetics (Anhui Medical University), Hefei, Anhui, China
- Yu Ren
- Biopreservation and Artificial Organs, Anhui Provincial Engineering Research Center, Anhui Medical University, Hefei, Anhui, China
- Zhiguo Zhang
- Reproductive Medicine Center, Department of Obstetrics and Gynecology, the First Affiliated Hospital of Anhui Medical University, Hefei, China
- Zhiguo Zhang
- Anhui Province Key Laboratory of Reproductive Health and Genetics (Anhui Medical University), Hefei, Anhui, China
- Zhiguo Zhang
- Biopreservation and Artificial Organs, Anhui Provincial Engineering Research Center, Anhui Medical University, Hefei, Anhui, China
- Ping Zhou
- Reproductive Medicine Center, Department of Obstetrics and Gynecology, the First Affiliated Hospital of Anhui Medical University, Hefei, China
- Ping Zhou
- Anhui Province Key Laboratory of Reproductive Health and Genetics (Anhui Medical University), Hefei, Anhui, China
- Ping Zhou
- Biopreservation and Artificial Organs, Anhui Provincial Engineering Research Center, Anhui Medical University, Hefei, Anhui, China
- Zhaolian Wei
- Reproductive Medicine Center, Department of Obstetrics and Gynecology, the First Affiliated Hospital of Anhui Medical University, Hefei, China
- Zhaolian Wei
- Anhui Province Key Laboratory of Reproductive Health and Genetics (Anhui Medical University), Hefei, Anhui, China
- Zhaolian Wei
- Biopreservation and Artificial Organs, Anhui Provincial Engineering Research Center, Anhui Medical University, Hefei, Anhui, China
- Huijuan Zou
- Reproductive Medicine Center, Department of Obstetrics and Gynecology, the First Affiliated Hospital of Anhui Medical University, Hefei, China
- Huijuan Zou
- National Health Commission (NHC) Key Laboratory of Study on Abnormal Gametes and Reproductive Tract (Anhui Medical University), Hefei, China
- Huijuan Zou
- Key Laboratory of Population Health Across Life Cycle (Anhui Medical University), Ministry of Education of the People’s Republic of China, Hefei, Anhui, China
- Yunxia Cao
- Reproductive Medicine Center, Department of Obstetrics and Gynecology, the First Affiliated Hospital of Anhui Medical University, Hefei, China
- Yunxia Cao
- National Health Commission (NHC) Key Laboratory of Study on Abnormal Gametes and Reproductive Tract (Anhui Medical University), Hefei, China
- Yunxia Cao
- Key Laboratory of Population Health Across Life Cycle (Anhui Medical University), Ministry of Education of the People’s Republic of China, Hefei, Anhui, China
- DOI
- https://doi.org/10.3389/fendo.2022.914030
- Journal volume & issue
-
Vol. 13
Abstract
BackgroundHigh mobility group box protein 1 (HMGB1) is considered as a kind of sterile inflammatory mediators, which is an overexpression in patients with unexplained recurrent spontaneous abortion (URSA). Specific targeting effect of aspirin on HMGB1 has been revealed. Our previous studies have explored the application of HMGB1 as a therapeutic target of aspirin in URSA disease of mice model and human, but the dynamic process of aspirin downregulating HMGB1 concentration has not been demonstrated.MethodsFrom December 2018 to November 2020, women with URSA (n = 91) and control women (n = 90) with no history of recurrent abortion or adverse pregnancy were included in the Reproductive Medicine Center of the First Affiliated Hospital of Anhui Medical University. ELISA was applied to detect the concentrations of HMGB1 and IFN-γ in the peripheral blood. Thirty-one URSA patients were monitored for low-dose aspirin treatment (2 and 4 weeks), the changes of HMGB1 and IFN-γ concentrations in peripheral blood of URSA patients before and after using aspirin were compared, and pregnancy outcomes after aspirin treatment were followed up.ResultsThe levels of HMGB1 in peripheral blood were significantly higher in URSA patients compared with controls, decreasing trends of HMGB1 and IFN-γ concentrations in plasma of URSA patients were observed after treatment with low-dose aspirin continuously, and the expression of HMGB1 was positively correlated with IFN-γ. There were no birth abnormalities in the babies of the URSA patients treated with aspirin.ConclusionsHigh levels of HMGB1 may be one of the pathogenesis of URSA. Low-dose aspirin may provide protective effect on the HMGB1-triggered URSA.
Keywords
- aspirin
- high mobility group box protein 1
- unexplained recurrent spontaneous abortion
- inflammation
- pregnancy